SSAA09E2 - 10mM in DMSO , CAS No.883944-52-3

CAS: 883944-52-3 Cat. No.: S656255 Formula: C16H20N4O2 Peso molecolare: 300.36 PubChem CID: 2738575
Disponibile su ordine
QUALITÀ & PUREZZA 10mM in DMSO
Storage
Protected from light,Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Dimensione
Germania (EU)
USA*
Prezzo
Qtà
1ml
S656255-1ml
Su ordinazione · 8–12 settimane
69,33€
Enter a quantity for the sizes you want to add.

Panoramica

SSAA09E2 is an inhibitor of SARS-CoV (Severe acute respiratory syndrome-Coronavirus) replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV , Angiotensin Converting Enzyme-2 (ACE2)

IC50& Target:SARS-CoV

Specifiche

Specifiche e purezza
10mM in DMSO
Meccanismi biochimici e fisiologici
SSAA09E2 is an inhibitor of SARS-CoV (Severe acute respiratory syndrome-Coronavirus) replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV , Angiotensin Converting Enzyme-2 (ACE2).
Condizioni di conservazione di stoccaggio
Protected from light,Store at -80°C
Spedito in
Dry ice packs + Cold packs
Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.
Nomi e identificatori
Isomeri SMILES
CN1CCN(CC1)C2=CC=C(C=C2)CNC(=O)C3=CC=NO3
PubChem CID
2738575
Termini MeSH
N-((4-(4-methylpiperazin-1-yl)phenyl)methyl)-1,2-oxazole-5-carboxamide;SSAA09E2
Peso molecolare
300.36

Dati avanzati

Certificati (CoA, COO, BSE/TSE e tabella di analisi)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calcolatori di soluzioni
Recensioni

Recensioni dei clienti

Application Protocols

No vendor-tested application protocols are provided for this SKU. The following general protocol outlines handling of small molecules in biochemical or cell-based assays:

General small-molecule stock preparation:

  • Equilibrate vial to room temperature in the dark before opening to avoid condensation.
  • Prepare a 10–50 mM stock in anhydrous DMSO. Vortex and, if needed, sonicate briefly. Filter through a 0.2 µm PTFE syringe filter if particulate persists.
  • Aliquot into amber microvials to minimize freeze–thaw; store at −80 °C.

Assay dosing:

  • Dilute stock into assay buffer or media to the desired concentration, keeping final DMSO ≤0.1–0.5% for cells (≤1–2% for biochemical assays).
  • Include vehicle controls and, where known, positive/negative control compounds.
  • Protect plates and solutions from light per the storage guidance.

Analytical QC before use:

  • Confirm identity/purity by LC‑MS and HPLC/UPLC. Document retention time, MS ion(s), and purity method.

Note: Replace this general guidance with your lab’s validated SOPs once the compound’s exact solubility, stability, and target context are established.

Biological Roles

Item-specific biological function, targets, or pathway roles are not provided in the Product Data for SSAA09E2.

General guidance for researchers:

  • Use the CAS (883944-52-3) and PubChem CID (2738575) to locate peer-reviewed literature describing any reported biochemical activity, target class, or phenotype. Verify that literature corresponds exactly to the same structure and stereochemistry, if any.
  • Prior to cellular work, confirm compound integrity (purity, identity) and evaluate nonspecific effects (detergent-like behavior, fluorescence interference, redox activity) using counterscreens such as aggregation controls (0.01–0.1% Triton X‑100), redox/thiol reactivity assays, and fluorescence quench checks.
  • Establish vehicle controls at the maximum DMSO percentage used in assays (typically 0.1–0.5% v/v for cell-based, up to 1–2% for biochemical assays).
  • If reported as light-sensitive in storage conditions, minimize light during dosing and plate handling to avoid photodegradation or photoactivity artifacts.

Data reporting best practices:

  • Include lot number, confirmed purity/identity data, exact solvent system, and final vehicle percentage in publications to ensure reproducibility.
  • Where applicable, generate basic ADME surrogate data (e.g., kinetic solubility, PAMPA or parallel artificial membrane permeability, microsomal stability) to interpret activity results. These should be tailored once the exact structure is confirmed.
Buffer Applications

This product is a small-molecule research compound and is not a buffering agent. Therefore, conventional buffer system guidance (e.g., pKa-based buffer selection, recipe tables) does not apply.

Practical notes for assay buffers (general):

  • Prepare compound stocks in DMSO or another suitable solvent, then dilute into assay buffer (e.g., PBS, HEPES, Tris) keeping the final organic cosolvent ≤0.1–1% v/v to maintain biological compatibility.
  • If the compound is ionizable (structure not provided), buffer pH can influence solubility and binding; pilot test at the intended pH range.
  • To mitigate adsorption or precipitation, include 0.01–0.1% nonionic surfactant (Tween-20 or Pluronic F‑127) where assay design permits, and pre-wet plasticware.
  • Protect solutions from light during preparation and assay in line with the storage note (“Protected from light”).
Green Alternatives

This product is a discrete small-molecule research compound rather than a process solvent or reagent used in bulk. “Green alternative” considerations are therefore limited and context-dependent.

  • Solvent choices: The primary environmental lever is the selection of greener solvents for dissolution, chromatography, and workup. Prefer ethanol, isopropanol, ethyl acetate, 2‑methyltetrahydrofuran (2‑MeTHF), or cyclopentyl methyl ether (CPME) over chlorinated solvents when compatible with the compound’s stability and assay needs.
  • Minimizing DMSO: While DMSO is relatively benign, aim to minimize DMSO usage and waste by preparing concentrated stocks and using microvolumes for dosing to reduce total solvent consumption.
  • Analytical methods: Use water-rich mobile phases and volatile buffers (ammonium acetate/formate) to reduce organic solvent usage and facilitate waste treatment.
  • Scale considerations: If the compound is used as a reference standard, maintain micro-scale operations to reduce chemical footprint (aliquoting to avoid thaw-refreeze and discard).

Trade-offs:

  • Greener solvents may not match the solubilizing power of DMSO/DMF for hydrophobic analytes; a small percentage of a stronger cosolvent may still be necessary.
  • Light protection requirements may necessitate amber plastics/glass; select recyclable materials where compatible with quality requirements.
Pharmaceutical Uses

No pharmacopeial status or excipient role is provided for this item. It is supplied strictly for research use only (non-clinical, non-diagnostic).

Contextual guidance (general):

  • If the compound is used as an internal reference standard in pharmaceutical analytics, document lot-specific purity, residual solvents, and water content (if available) and verify with in-house methods prior to use.
  • For pre-formulation research (in vitro only), assess solubility in biorelevant media (FaSSIF/FeSSIF simulants) and compatibility with common excipients, recognizing that this product is not manufactured under cGMP nor intended for human or veterinary use.
  • Do not incorporate into any clinical materials or GLP toxicology studies without appropriate qualification, sourcing, and regulatory compliance.
Physical Properties

Item-specific physicochemical properties were not provided.

  • Appearance/physical state: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point: Not specified for this item; refer to CoA/Spec Sheet.
  • Boiling point: Not applicable/Not specified; solid small molecules are typically characterized by mp (literature values should be confirmed against the exact structure).
  • Density: Not specified for this item; refer to CoA/Spec Sheet.
  • Refractive index: Not applicable for solids; Not specified for this item.
  • pKa/logP/logD: Not specified for this item; consult literature once the exact structure is confirmed.
  • Solubility: Not specified for this item; typical practice is to prepare analytical stocks in anhydrous DMSO and evaluate aqueous tolerance by serial dilution with buffer containing cosolvent (see Solvent Selection).

Practical guidance (general):

  • Establish a solubility screen in: DMSO, DMF, ethanol, methanol, acetonitrile, and PBS with 0.5–2% DMSO (v/v). Verify clarity and absence of precipitation over 24 h at intended assay temperature.
  • For analytical work, begin with LC‑MS compatible diluents (water/acetonitrile or water/methanol with 0.1% formic acid or ammonium acetate) after a primary DMSO stock. Confirm stability under autosampler conditions (4–10°C) and light exposure.
  • If hygroscopicity or polymorphism is a concern, consult the CoA for loss-on-drying and XRPD/DSC notes when available.
Quality and Grades
  • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.

Interpreting quality information (general guidance):

  • Purity determination: For small molecules used in screening or reference applications, purity is commonly established by HPLC/UPLC (UV or CAD/ELSD) and/or NMR integration. Confirm the analytical technique and detection wavelength on the CoA, as UV-only assays may under-report non-UV impurities.
  • Identity confirmation: Look for combined evidence (1H NMR, 13C NMR, HRMS/ESI, and, where relevant, IR). Chiral compounds may require chiral HPLC or optical rotation.
  • Residual solvents and water: If Karl Fischer (KF) moisture or GC residual solvent data are critical for your application (e.g., quantitative biology, solid-state formulation), request the latest lot-specific CoA.
  • Stabilizers/inhibitors: None are listed for this item. If the molecule is oxidation- or hydrolysis-prone, suppliers may include stabilizers; verify on the CoA before using in sensitive assays.

Fit-for-purpose selection:

  • For bioassay screening and reference standard use, >=95–98% HPLC purity is typically targeted (literature practice). If you require trace-metal, endotoxin, or UV-cutoff specifications for specialized analytics, contact Technical Support with your method requirements.
Reaction and Applications

No manufacturer application details were provided for this SKU beyond “Research use only,” and the structure is not disclosed here. Accordingly, reaction chemistry guidance must remain general.

Potential research uses (general):

  • Reference compound or tool molecule in phenotypic or target-based screening. Prepare DMSO stocks, confirm identity/purity by LC‑MS/NMR prior to critical studies.
  • Analytical system suitability: May be used as a positive/negative control in assay development once its biochemical context is confirmed from primary literature associated with the CAS/CID.
  • Method development: Serves as a test article for optimizing LC‑MS ionization, retention, and recovery on various stationary phases (C18, phenyl-hexyl, HILIC) depending on its polarity when known.

If synthetic applications are intended:

  • Without structural information, specific reactivity (e.g., cross-coupling handles, carbonyl chemistry) cannot be defined. Obtain the exact structure and functional groups before planning derivatizations, stability studies, or prodrug strategies.

Practical tips:

  • Establish a chain-of-custody and analytical confirmation (1H NMR, HRMS, HPLC purity) upon receipt.
  • For biological assays, pre-validate the working concentration range by solubility limit tests and vehicle controls (0.1–1% DMSO).
  • Given light sensitivity in storage instructions, minimize exposure during all assay and analytical workflows.
Reaction Conditions

Because the structure and functional groups of SSAA09E2 are not provided in the Product Data, no specific reaction conditions can be recommended. General guidance is below for common small-molecule manipulations after the structure is confirmed:

  • Couplings (amide/ester): EDCI/HOBt or HATU/HOAt in DMF/DMF-DCM; DIPEA or collidine as base; 0–25 °C for 1–16 h (literature, general).
  • Cross-couplings: Pd(0) or Pd(II) catalysts (e.g., XPhos/Pd-PEPPSI) in dioxane, toluene, or CPME; 60–120 °C with base (K2CO3, Cs2CO3) under inert atmosphere (literature, general).
  • Reductive aminations: NaBH(OAc)3 in DCE/MeOH or BH3·THF; 0–25 °C (literature, general).
  • Hydrogenations: Pd/C (5–10%) under H2 (1–5 bar) in EtOH/EtOAc; 20–40 °C (literature, general).
  • Photoredox: Ir(ppy)3 or Ru(bpy)3Cl2 with blue LEDs in MeCN/MeOH or DMSO; 20–30 °C (literature, general).

Analytical controls:

  • Monitor by LC‑MS and/or UPLC‑UV at multiple wavelengths. Confirm mass balance and impurity profile, especially if the end use is as a research standard.
  • Given the storage note “Protected from light,” avoid prolonged high-intensity light during photochemical steps unless intentional and tested for stability.

These suggestions are generic and must be tailored once the exact structure of SSAA09E2 is verified.

Safety and Handling

Safety data for this specific item were not provided; treat as a research chemical of unknown hazard profile.

  • GHS classification: Not specified for this item; refer to SDS.
  • Signal word and H-statements: Not specified for this item; refer to SDS.
  • Pictograms: Not specified for this item; refer to SDS.

General laboratory precautions (best practice):

  • PPE: Use lab coat, safety glasses, and disposable nitrile gloves; upgrade to splash goggles and double-gloving for weighing powders or preparing concentrated solutions.
  • Engineering controls: Handle powders and solutions in a certified chemical fume hood. Avoid aerosol generation; use closed-tip pipettes.
  • Incompatibilities: Unknown for this item. As a conservative approach, avoid strong oxidizers, strong acids/bases, and reducing agents until compatibility is verified.
  • Light sensitivity: Product Data indicates “Protected from light”; minimize light exposure during handling and storage (use amber vials/aluminum foil).
  • Cryogenic handling: Shipped on dry ice/cold packs. Open shipments carefully to avoid cold burns and condensation ingress.

First-aid overview (refer to SDS for authoritative guidance):

  • Inhalation: Move to fresh air; seek medical attention if symptoms persist.
  • Skin/eye contact: Rinse with water for 15 minutes; remove contaminated clothing.
  • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.

Waste: Collect in appropriate organic waste compatible with your institution’s hazardous waste stream. Decontaminate surfaces with suitable solvents/detergents consistent with the chosen vehicle (e.g., DMSO/EtOH).

Solvent Selection

Item-specific solubility data are not provided. The following is general, fit-for-purpose guidance for small molecules of unknown solubility profile.

  • Primary stock solvent: DMSO is the default due to broad solubilizing power and compatibility with biochemical assays at low final v/v (≤0.1–1%). Start at 10–50 mM stocks.
  • Screening panel: Evaluate solubility and stability in:
    • Polar aprotic: DMSO, DMF, NMP, acetonitrile.
    • Protic: methanol, ethanol, isopropanol.
    • Aqueous: PBS or assay buffer with 0.1–2% DMSO or ethanol.
    • Nonpolar (for workups): ethyl acetate, MTBE, dichloromethane, toluene (as relevant for purification, not cell assays).
  • pH effects: If the compound is ionizable (unknown here), apparent solubility can be tuned by pH. Use volatile buffers (e.g., ammonium bicarbonate) for LC‑MS compatibility.
  • Filtration: Use 0.2 µm PTFE or PVDF for organic-rich solutions; use PES or nylon cautiously due to possible adsorption of hydrophobic analytes.
  • Stability checks: Assess for precipitation, color change, or UV/LC‑MS peak degradation over 24–48 h at bench, 4 °C, and autosampler conditions. Given “Protected from light,” conduct tests in amberware.

Comparison (general):

  • DMSO vs DMF: DMSO is more biocompatible at low %; DMF may offer higher solubility for some heteroaromatics but is less assay-friendly.
  • Aqueous cosolvent systems: 0.5–1% DMSO typically balances solubility and cell tolerance better than ethanol for many assays.
Storage and Reconstitution
  • Storage conditions (as provided): Protected from light; Store at −80 °C.
  • Shipping: Dry ice packs + Cold packs (receive promptly; do not leave at ambient temperature).

Best practices:

  • Upon receipt, inspect the package, then transfer immediately to −80 °C in light-protective secondary containment (amber box or foil-wrapped vial).
  • Allow the sealed container to warm to room temperature before opening to prevent moisture condensation. Open under low humidity if possible.
  • If a solid, minimize headspace and promptly re-cap under dry air or inert gas after each use. If a solution, maintain in anhydrous solvent (commonly DMSO) and avoid repeated freeze–thaw by aliquoting.
  • Reconstitution: Solvent choice is item-dependent and not specified. DMSO is generally preferred for initial stock solutions. Start at 10–50 mM, then dilute into the intended assay buffer keeping final organic cosolvent low (≤0.1–1% v/v). Verify clarity and stability.
  • Light protection: Use amber vials and minimize exposure during weighing, dissolution, and storage.
  • Stability/shelf life: Not specified for this item; refer to CoA/Spec Sheet. Establish in-house stability indicating methods (LC‑MS/HPLC) and time-in-storage logs for critical applications.

Research Use Notice: For research use only; not for human or veterinary use.

Structure and Identity

Brief overview: SSAA09E2 is a cataloged small molecule supplied for research use. Limited item-specific structural details are provided for this SKU.

  • SKU: S656255
  • Product name: SSAA09E2
  • CAS: 883944-52-3 (identifier provided; structure not provided in this listing)
  • PubChem CID: 2738575 (public database identifier; consult for supplemental literature data)
  • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general notes):

  • Item-specific functional groups, ring systems, and stereochemistry are not provided in the Product Data.
  • If structural elucidation is required for method development (e.g., LC‑MS, NMR), obtain the structure from the supplied CoA/Spec Sheet or trusted databases linked to the CAS/CID above.

2D structure (descriptive):

  • Not described here due to missing structural fields. Please reference the CoA or authoritative databases for an annotated 2D depiction suitable for analytical method setup (fragmentation pathways, UV chromophores, isotopic patterns).
Synthetic Utility

Synthetic transformation guidance cannot be provided without the compound’s structure and functional groups. The following are general considerations if derivatization or analog synthesis is contemplated after confirming the exact structure:

  • Handle identification: Map reactive handles (e.g., aryl halides for cross-coupling, carbonyls for reductive amination, carboxylic acids for amide coupling, phenols for etherification) before route design.
  • Protecting-group strategy: If multiple nucleophiles/electrophiles coexist, employ orthogonal protection to enable selective transformations.
  • Late-stage diversification: Consider C–H activation, SuFEx, or photoredox methods for rapid analog generation if the scaffold supports them.
  • Purification: Choose normal-phase silica, reverse-phase prep LC, or crystallization according to polarity/logP once known. Monitor with orthogonal analytics (UV at multiple wavelengths and MS).
  • Stability: Evaluate hydrolytic/oxidative sensitivity (peroxide-prone moieties, base/acid labile linkages) before scaling reactions.

For precise synthetic planning, retrieve the full structural information from the CoA or the cited identifiers (CAS/CID) and cross-check with primary literature.

Target Specificity

No target, pathway, or binding specificity is provided in the Product Data for SSAA09E2.

  • Item-specific biological targets, Ki/IC50 values, or selectivity panels: Not specified for this item; refer to CoA/Spec Sheet and primary literature linked via CAS 883944-52-3 or PubChem CID 2738575.
  • Species reactivity, clone, isotype: Not applicable; this is not an antibody or protein reagent.

Recommendation:

  • If using SSAA09E2 as a tool compound, confirm reported targets with orthogonal assays (biochemical and cellular), include counter-screens for common assay interferences, and report lot information and assay conditions for reproducibility.

Desidera che le inviamo un messaggio quando avremo sconti disponibili?

Ricordamelo più tardi

Grazie! Controlli la sua casella di posta per confermare.

Ops! Le notifiche sono disabilitate.